Status:
Ready to upload
Record number:
2359
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
538 adverse reactions per 100,000 transfusions: red blood cells: 577 per 100,000; platelets: 833 per 100,000
Time to detection:
The study considered both acute and delayed transfusion reactions.
Alerting signals, symptoms, evidence of occurrence:
The different types of transfusion reactions included in this paper are well described. Statistically higher rates of allergic reactions, febrile nonhemolytic reactions and acute hemolytic reactions were observed in pediatric patients.
Demonstration of imputability or root cause:
The issue of imputability is addressed (Materials and Methods page 62).
Imputability grade:
Not Assessable
Groups audience:
Keywords:
Reference attachment:
Suggest references:
Analysis of pediatric adverse reactions to transfusions. Transfusion. 2018 Jan;58(1):60-69
Note:
The system does not allow to indicate more than one product, or more than one transfusion reaction. I did not indicate an imputability grade since this is a retrospective study on a high number of cases.
This record has been cloned for the 4 different transfusion reactions (EP)
Expert comments for publication:
This is a large retrospective study conducted in 9 children's hospitals and 35 adult hospitals between January 2009 through December 2015. It's aims were to expand knowledge on pediatric patients' responses to transfusions and evaluate differences between adult and pediatric rates and within pediatric and neonatal populations. The methodological approach is convincing, definitions of adverse events, severity grade and imputability criteria standardized and exclusion criteria are clearly stated. A total of 3822 transfusion reactions were reported from 1,222,689 transfused components. Results indicate that the pediatric transfusion reaction rate (538 per 100,000) is significantly higher than the adult reaction rate (252 per 100,000). The analysis takes into consideration blood product and type of reaction. Moreover, it compares transfusion reactions in neonatal (< 30 days) and nonneonatal (30 days to 18 years) patients. In the discussion, Authors compare their results with other hemovigilance systems (SHOT, Troll, DART, TRIP), provide interpretation on their findings and comment on the limitations of their study. This study provides a significant contribution to the important area of transfusion safety in the pediatric population.